December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Anixa Biosciences Inc (NQ: ANIX )

3.080 -0.050 (-1.60%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 110,408
Open 3.150
Bid (Size) 3.050 (433)
Ask (Size) 3.200 (3)
Prev. Close 3.130
Today's Range 3.050 - 3.180
52wk Range 2.145 - 5.130
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Anixa Biosciences And 3 Other Stocks Under $5 Insiders Are Buying
Via Benzinga

Performance

YTD
-21.63%
-21.63%
1 Month
+0.65%
+0.65%
3 Month
-0.96%
-0.96%
6 Month
+8.07%
+8.07%
1 Year
+6.94%
+6.94%

More News

Read More
EXCLUSIVE: FDA Approves Anixa Biosciences' Individual Patient Trial Application For Ovarian Cancer CAR-T Therapy
Via Benzinga
Exposures Product Safety
EXCLUSIVE: Anixa Biosciences Finds Stock Undervalued, Launches $5M Stock Buyback Program
Via Benzinga
ANIX Stock Earnings: Anixa Biosciences Beats EPS for Q2 2024
Via InvestorPlace
Recap: Anixa Biosciences Q1 Earnings
Via Benzinga
6 Analysts Have This to Say About Anixa Biosciences
Via Benzinga
The Latest Analyst Ratings for Anixa Biosciences
Via Benzinga
Expert Ratings for Anixa Biosciences
Via Benzinga
7 Penny Biotech Stocks to Triple Your Investment
Via InvestorPlace
Anixa Biosciences, Inc. (NASDAQ: ANIX) Featured in Coverage of the EF Hutton Annual Global Conference
Via Investor Brand Network
Sidoti Events, LLC's Virtual May Micro-Cap Conference
Via ACCESSWIRE
Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth
Via AB Newswire
Sidoti Events, LLC's Virtual January Micro-Cap Conference
Via ACCESSWIRE
Anixa Biosciences, A New Type Of Biotech Company: Could It Disrupt The Cancer Landscape?
Via Benzinga
3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023
Via InvestorPlace
Anixa Biosciences Reveals Updated Data From Breast Cancer Vaccine Trial, Says 'Exceeded Expectations'
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
The 3 Most Undervalued Cheap Stocks to Buy in September 2023
Via InvestorPlace
Could Anixa Biosciences (NASDAQ:ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?
Via ACCESSWIRE
Could Anixa Biosciences (NASDAQ: ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?
Via Benzinga
Anixa Biosciences And 2 Other Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Appreciating The Passing Of A Titan & Incorporating Alternative Data Signals
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For December 23, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.